Haleon plc
HLN.LHealthcareLSEDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHaleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa,. Valued at $30.25B, HLN.L is a large-cap name in its sector. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Market Cap
$30.25B
Beta
0.25
P/E (TTM)
17.98
P/E (Fwd)
15.18
EPS (TTM)
$0.19
EPS (Fwd)
$0.23
ROE
10.3%
ROA
4.7%
Cash
$1.35B
Total Debt
$8.63B
Free CF
$1.40B
52W Change
-16.2%
Annual Financials
Cash vs Debt
The company holds $1.35B in cash, though total debt stands at $8.63B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $1.40B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 10.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $10.86B (2022) to $11.03B (2025).
With a beta below 0.7, Haleon plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing HLN.L's risk profile alongside its fundamentals and technical indicators provides a more complete picture.